AGIO

Agios Pharmaceuticals Stock Price

38.46
-0.21 (-0.54%)
Upgrade to Real-Time
Afterhours (Closed)
38.46
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Small Cap Pro
Monthly Subscription
for only
$49.05
DDE w/Realtime (Monthly)
Monthly Subscription
for only
$34.10
VAT not included
Company Name Stock Ticker Symbol Market Type
Agios Pharmaceuticals Inc AGIO NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.21 -0.54% 38.46 17:15:00
Close Price Low Price High Price Open Price Previous Close
38.46 37.67 38.99 38.99 38.67
Bid Price Ask Price Spread News
36.00 40.78 4.78 - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
7,380 987,226 $ 38.35 $ 37,855,688 586,791 27.774 - 56.745
Last Trade Time Type Quantity Stock Price Currency
16:28:14 priorref 17,360 $ 38.46 USD

Agios Pharmaceuticals Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 2.66B 69.11M 44.63M $ 117.91M $ - -6.86 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Agios Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical AGIO Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week38.4239.248236.9138.07447,5290.040.1%
1 Month39.8541.7835.6839.26539,193-1.39-3.49%
3 Months52.6156.74535.6845.36563,227-14.15-26.9%
6 Months30.7856.74527.77444.61655,8737.6824.95%
1 Year36.7256.74527.77442.71716,6601.744.74%
3 Years67.0099.824227.77454.59553,490-28.54-42.6%
5 Years95.3499.824227.77453.17597,169-56.88-59.66%

Agios Pharmaceuticals Description

Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development strategy for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.


Your Recent History
NASDAQ
AGIO
Agios Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.